Elsevier

Clinical Therapeutics

Volume 30, Issue 7, July 2008, Pages 1206-1227
Clinical Therapeutics

Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: An update

https://doi.org/10.1016/S0149-2918(08)80047-1Get rights and content

Abstract

Background: The second-generation antidepressants include selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), and other compounds with different mechanisms of action. All second-generation antidepressants are metabolized in the liver by the cytochrome P450 (CYP) enzyme system. Concomitant intake of inhibitors or inducers of the CYP isozymes involved in the biotransformation of specific antidepressants may alter plasma concentrations of these agents, although this effect is unlikely to be associated with clinically relevant interactions. Rather, concern about drug interactions with second-generation antidepressants is based on their in vitro potential to inhibit ≥1 CYP isozyme.

Objective: The goal of this article was to review the current literature on clinically relevant pharmacokinetic drug interactions with second-generation antidepressants.

Methods: A search of MEDLINE and EMBASE was conducted for original research and review articles published in English between January 1985 and February 2008. Among the search terms were drug interactions, second-generation antidepressants, newer antidepressants, SSRIs, SNRIs, fluoxetine, paroxetine, fluvoxamine, sertraline, citalopram, escitalopram, venlafaxine, duloxetine, mirtazapine, reboxetine, bupropion, nefazodone, pharmacokinetics, drug metabolism, and cytochrome P450. Only articles published in peerreviewed journals were included, and meeting abstracts were excluded. The reference lists of relevant articles were hand-searched for additional publications.

Results: Second-generation antidepressants differ in their potential for pharmacokinetic drug interactions. Fluoxetine and paroxetine are potent inhibitors of CYP2D6, fluvoxamine markedly inhibits CYP1A2 and CYP2C19, and nefazodone is a substantial inhibitor of CYP3A4. Therefore, clinically relevant interactions may be expected when these antidepressants are coadministered with substrates of the pertinent isozymes, particularly those with a narrow therapeutic index. Duloxetine and bupropion are moderate inhibitors of CYP2D6, and sertraline may cause significant inhibition of this isoform, but only at high doses. Citalopram, escitalopram, venlafaxine, mirtazapine, and reboxetine are weak or negligible inhibitors of CYP isozymes in vitro and are less likely than other second-generation antidepressants to interact with co-administered medications.

Conclusions: Second-generation antidepressants are not equivalent in their potential for pharmacokinetic drug interactions. Although interactions may be predictable in specific circumstances, use of an antidepressant with a more favorable drug-interaction profile may be justified.

References (181)

  • National Institute for Clinical Excellence

    Depression: Management of Depression in Primary and Secondary Care

    Clinical Guideline 23

    (2004)
  • CB Nemeroff

    Prevalence and management of treatmentresistant depression

    J Clin Psychiatry

    (2007)
  • E Spina et al.

    Newer and older antidepressants: A comparative review of drug interactions

    CNS Drugs

    (1994)
  • CB Nemeroff et al.

    Newer antidepressants and the cytochrome P450 system

    Am J Psychiatry

    (1996)
  • RM Lane

    Pharmacokinetic drug interaction potential of selective serotonin reuptake inhibitors [published correction appears in Int Clin Psychopharmacol. 1997;12:126]

    Int Clin Psychopharmacol

    (1996)
  • DJ Greenblatt et al.

    Drug interactions with newer antidepressants: Role of human cytochromes P450

    J Clin Psychiatry

    (1998)
  • A Hemeryck et al.

    Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions: An update

    Curr Drug Metab

    (2002)
  • E Spina et al.

    Metabolic drug interactions with new psychotropic agents

    Fundam Clin Pharmacol

    (2003)
  • KL Cozza et al.
  • DR Nelson et al.

    P450 Superfamily: Update on new sequences, gene mapping, accession numbers and nomenclature

    Pharmacogenetics

    (1996)
  • JH Lin et al.

    Inhibition and induction of cytochrome P450 and the clinical implications

    Clin Pharmacokinet

    (1998)
  • KE Thummel et al.

    Metabolically-based drug-drug interactions: Principles and mechanisms

  • BA Sproule et al.

    Selective serotonin reuptake inhibitors and CNS drug interactions. A critical review of the evidence

    Clin Pharmacokinet

    (1997)
  • P Baumann et al.

    The AGNP-TDM expert group consensus guidelines: Therapeutic drug monitoring in psychiatry

    Pharmacopsychiatry

    (2004)
  • E Spina et al.

    Clinically significant drug interactions with antidepressants in the elderly

    Drugs & Aging

    (2002)
  • MU Shad et al.

    Antidepressants

  • HK Crewe et al.

    The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes

    Br J Clin Pharmacol

    (1992)
  • J Schmider et al.

    Inhibition of CYP2C9 by selective serotonin reuptake inhibitors in vitro: Studies of phenytoin p-hydroxylaton

    Br J Clin Pharmacol

    (1997)
  • K Kobayashi et al.

    The effects of selective serotonin reuptake inhibitors and their metabolites on S-mephenytoin 4'-hydroxylase activity in human liver microsomes

    Br J Clin Pharmacol

    (1995)
  • DJ Greenblatt et al.

    Inhibition of human cytochrome P450-3A isoforms by fluoxetine and norfluoxetine: In vitro and in vivo studies

    J Clin Pharmacol

    (1996)
  • AB Aranow et al.

    Elevated antidepressant plasma levels after addition of fluoxetine

    Am J Psychiatry

    (1989)
  • J Westermeyer

    Fluoxetine-induced tricyclic toxicity: Extent and duration

    J Clin Pharmacol

    (1991)
  • RF Bergstrom et al.

    Quantification and mechanism of the fluoxetine and tricyclic antidepressaant interaction

    Clin Pharmacol Ther

    (1992)
  • SH Preskorn et al.

    Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine

    J Clin Psychopharmacol

    (1994)
  • A Avenoso et al.

    Interaction between fluoxetine and haloperidol: Pharmacokinetic and clinical implications

    Pharmacol Res

    (1997)
  • F Centorrino et al.

    Serum concentrations of clozapine and its major metabolites: Effects of cotreatment with fluoxetine or valproate

    Am J Psychiatry

    (1994)
  • F Centorrino et al.

    Serum levels of clozapine and norclozapine in patients treated with selective serotonin reuptake inhibitors

    Am J Psychiatry

    (1996)
  • E Spina et al.

    Effect of fluoxetine on the plasma concentrations of clozapine and its major metabolites in patients with schizophrenia

    Int Clin Psycho pharmacol

    (1998)
  • E Spina et al.

    Inhibition of risperidone metabolism by fluoxetine in patients with schizophrenia: A clinically relevant pharmacokinetic drug interaction

    J Clin Psychopharmacol

    (2002)
  • G Bondolfi et al.

    The effect of fluoxetine on the pharmacokinetics and safety of risperidone in psychotic patients

    Pharmacopsychiatry

    (2002)
  • D Gossen et al.

    Influence of fluoxetine on olanzapine pharmacokinetics

    AAPS PharmSci

    (2002)
  • SG Potkin et al.

    Effect of fluoxetine and imipramine on the pharmacokinetics and tolerabilitty of the antipsychotic quetiapine

    J Clin Psychopharmacol

    (2002)
  • E Spina et al.

    Metabolic drug interactions with newer antipsychotics: A comparative review

    Basic Clin Pharmacol Toxicol

    (2007)
  • L Lemberger et al.

    The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam

    Clin Pharmacol Ther

    (1988)
  • DJ Greenblatt et al.

    Fluoxetine impairs clearance of alprazolam but not of clonazepam

    Clin Pharmacol Ther

    (1992)
  • HJ Pearson

    Interaction of fluoxetine with carbamazepine

    J Clin Psychiatry

    (1990)
  • SR Grimsley et al.

    Increased carbamazepine plasma concentrations after fluoxetine coadministration

    Clin Pharmacol Ther

    (1991)
  • E Spina et al.

    Carbamazepine coadministration with fluoxetine or fluvoxamine

    Ther Drug Monit

    (1993)
  • P Jalil

    Toxic reaction following the combined administration of fluoxetine and phenytoin: Two case reports

    J Neurol Neurosurg Psychiatry

    (1992)
  • DJ Woods et al.

    Interaction of phenytoin and fluoxetine [2]

    NZ Med J

    (1994)
  • Cited by (300)

    View all citing articles on Scopus
    View full text